Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Skin Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Merkel Cell Carcinoma (21
)
Squamous Cell Skin Cancer (20
)
Basal Cell Carcinoma (17
)
Merkel Cell Carcinoma (21
)
Squamous Cell Skin Cancer (20
)
Basal Cell Carcinoma (17
)
›
Associations
(986)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab/relatlimab
Sensitive: A1 - Approval
N Engl J Med - 3 weeks (New B)
nivolumab / relatlimab
Sensitive
:
A1
N Engl J Med - 3wk
nivolumab/relatlimab
Sensitive: A1 - Approval
N Engl J Med - 3 weeks
nivolumab / relatlimab
Sensitive
:
A1
N Engl J Med - 3 weeks - (New B)
No biomarker
Basal Cell Carcinoma
No biomarker
Basal Cell Carcinoma
fluorouracil topical
Sensitive: A1 - Approval
fluorouracil topical
Sensitive
:
A1
fluorouracil topical
Sensitive: A1 - Approval
fluorouracil topical
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
atezolizumab + vemurafenib + cobimetinib
Sensitive: A1 - Approval
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
No biomarker
Basal Cell Carcinoma
vismodegib
Sensitive: A1 - Approval
vismodegib
Sensitive
:
A1
vismodegib
Sensitive: A1 - Approval
vismodegib
Sensitive
:
A1
No biomarker
Merkel Cell Carcinoma
No biomarker
Merkel Cell Carcinoma
avelumab
Sensitive: A1 - Approval
avelumab
Sensitive
:
A1
avelumab
Sensitive: A1 - Approval
avelumab
Sensitive
:
A1
No biomarker
Merkel Cell Carcinoma
No biomarker
Merkel Cell Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
No biomarker
Basal Cell Carcinoma
imiquimod
Sensitive: A1 - Approval
imiquimod
Sensitive
:
A1
imiquimod
Sensitive: A1 - Approval
imiquimod
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
No biomarker
Melanoma
trametinib
Resistant: A1 - Approval
trametinib
Resistant
:
A1
trametinib
Resistant: A1 - Approval
trametinib
Resistant
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
vemurafenib
Sensitive: A1 - Approval
vemurafenib
Sensitive
:
A1
No biomarker
Basal Cell Carcinoma
No biomarker
Basal Cell Carcinoma
sonidegib
Sensitive: A1 - Approval
sonidegib
Sensitive
:
A1
sonidegib
Sensitive: A1 - Approval
sonidegib
Sensitive
:
A1
No biomarker
Cutaneous Melanoma
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
ipilimumab
Sensitive: A1 - Approval
ipilimumab
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
BRAF V600E
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
encorafenib + binimetinib
Sensitive: A1 - Approval
encorafenib + binimetinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
BRAF V600
Melanoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login